These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16906669)

  • 1. New black box warning for ritonavir-boosted tipranavir.
    Ryan CT
    AIDS Clin Care; 2006 Aug; 18(8):72. PubMed ID: 16906669
    [No Abstract]   [Full Text] [Related]  

  • 2. Tipranavir.
    Gallant J
    Drugs; 2003; 63(15):1619-20. PubMed ID: 12887269
    [No Abstract]   [Full Text] [Related]  

  • 3. New protease inhibitor offers clinicians hope for better salvage therapy.
    Murphy MJ
    HIV Clin; 2006; 18(1):1-3. PubMed ID: 16838417
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-HIV agents. Tipranavir in treatment-experienced PHAs.
    TreatmentUpdate; 2005; 17(1):4-5. PubMed ID: 17225315
    [No Abstract]   [Full Text] [Related]  

  • 5. Aptivus in the hotseat. Excerpts from the FDA hearings.
    Huff B
    GMHC Treat Issues; 2005; 19(5-6):6-8. PubMed ID: 16193577
    [No Abstract]   [Full Text] [Related]  

  • 6. Tipranavir: new drug. HIV protease inhibitor. A last resort.
    Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aptivus capsules granted full FDA approval.
    AIDS Patient Care STDS; 2007 Nov; 21(11):889-90. PubMed ID: 18338430
    [No Abstract]   [Full Text] [Related]  

  • 8. [Desensitization to tipranavir caused by toxicodermia].
    Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
    Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
    [No Abstract]   [Full Text] [Related]  

  • 9. Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.
    Celesia BM; Onorante A; Nunnari G; Mughini MT; Mavilla S; Massimino SD; Russo R
    AIDS; 2007 Jul; 21(11):1495-6. PubMed ID: 17589203
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study.
    Markowitz M; Slater LN; Schwartz R; Kazanjian PH; Hathaway B; Wheeler D; Goldman M; Neubacher D; Mayers D; Valdez H; McCallister S
    J Acquir Immune Defic Syndr; 2007 Aug; 45(4):401-10. PubMed ID: 17554217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA approval: tipranavir.
    Sax PE
    AIDS Clin Care; 2005 Aug; 17(8):78. PubMed ID: 16193574
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-HIV agents. Unexpected results from a tipranavir study.
    TreatmentUpdate; 2004; 16(3):6-7. PubMed ID: 17216836
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA approves tipranavir.
    IAPAC Mon; 2005 Jul; 11(7):190. PubMed ID: 16676422
    [No Abstract]   [Full Text] [Related]  

  • 14. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Morelló J; Garcia-Gascó P; Rodríguez-Novoa S; Soriano V
    Expert Opin Pharmacother; 2007 Apr; 8(6):839-50. PubMed ID: 17425479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
    Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
    Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tipranavir: therapeutic drug monitoring in a pediatric patient with HIV infection].
    Soler-Palacín P; Fàbrega A; María López R; Figueras C
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):133-4. PubMed ID: 19254645
    [No Abstract]   [Full Text] [Related]  

  • 17. Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System.
    Chan-Tack KM; Struble KA; Birnkrant DB
    AIDS Patient Care STDS; 2008 Nov; 22(11):843-50. PubMed ID: 19025478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracranial hemorrhage with Aptivu.
    AIDS Patient Care STDS; 2006 Dec; 20(12):889. PubMed ID: 17216876
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug interactions of tipranavir, a new HIV protease inhibitor.
    Morello J; Rodriguez-Novoa S; Jimenez-Nacher I; Soriano V
    Drug Metab Lett; 2007 Jan; 1(1):81-4. PubMed ID: 19356024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.
    Salazar JC; Cahn P; Yogev R; Negra MD; Castelli-Gattinara G; Fortuny C; Flynn PM; Giaquinto C; Ruan PK; Smith ME; Mikl J; Jelaska A;
    AIDS; 2008 Sep; 22(14):1789-98. PubMed ID: 18753862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.